Literature DB >> 11379338

Risk factors for recurrence of large HCC in patients treated by combined TAE and PEI.

S Arata1, K Tanaka, H Okazaki, M Kondo, M Morimoto, S Saito, K Numata, S Nakamura, H Sekihara.   

Abstract

BACKGROUND/AIMS: In this report, risk factors of intrahepatic recurrence of a large solitary hepatocellular carcinoma after combination therapy with transcatheter arterial embolization followed by percutaneous ethanol injection were studied.
METHODOLOGY: The series included 61 patients with an unresectable large solitary hepatocellular carcinoma, the largest size of which was greater than 3 cm in diameter. All patients completely responded to combination therapy and recurrence rates were determined. The following parameters; age, sex, hepatitis B virus surface antigen, hepatitis C virus antibodies, Child's classification, alcohol abuse, alanine aminotransferase, aspartate aminotransferase, alpha-fetoprotein, indocyanine green retention rate, hepatocellular carcinoma size, hepatocellular carcinoma capsule, total amount of injected ethanol and the alpha-fetoprotein 1 month after treatment were evaluated.
RESULTS: The 1-, 3-, and 5-year cancer-free survival rates of all patients were calculated to be 61%, 23%, and 13%, respectively. Among pretreatment parameters, the log-rank test and subsequent Cox's proportional hazards model showed that a tumor size of more than 5 cm in diameter was independently associated with recurrence. The posttreatment parameters of total amount of injected ethanol was also shown to be significantly related to recurrence by the log-rank test.
CONCLUSIONS: Lesions more than 5 cm in diameter and insufficient injected ethanol were associated with intrahepatic recurrence after this combination therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11379338

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  4 in total

1.  Curative effect of stereotactic body radiotherapy for unresectable massive primary liver cancer.

Authors:  Ya-Zheng Dang; Xin Li; Shi-Gao Huang; Wan-Ling Lu; Guodong Wang; Dongxian Zhang; Qian-Yun Wang
Journal:  Mol Clin Oncol       Date:  2017-05-09

2.  [Regression and therapy-resistance of primary liver tumors and liver metastases after regional chemotherapy and local tumor ablation].

Authors:  H-P Fischer
Journal:  Pathologe       Date:  2005-05       Impact factor: 1.011

3.  Experimental and clinical assessment of percutaneous hepatic quantified ethanol injection in treatment of hepatic carcinoma.

Authors:  Li-Wu Lin; Xue-Ying Lin; Yi-Mi He; Shang-Da Gao; En-Sheng Xue; Xiao-Dong Lin; Li-Yun Yu
Journal:  World J Gastroenterol       Date:  2004-11-01       Impact factor: 5.742

Review 4.  Incorporating GSA-SPECT into CT-based dose-volume histograms for advanced hepatocellular carcinoma radiotherapy.

Authors:  Shintaro Shirai; Morio Sato; Yasutaka Noda; Yoshitaka Kumayama; Noritaka Shimizu
Journal:  World J Radiol       Date:  2014-08-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.